Geoffrey I. Shapiro, MD, PhD

Associate Professor, Department of Medicine, Harvard Medical School

Associate Professor, Medical Oncology, Dana-Farber Cancer Institute

Director, Early Drug Development Center, Dana-Farber Cancer Institute

Contact Info

Geoffrey Shapiro
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Mayer 446
Phone: 617-632-4942
Fax: 617-632-1977
geoffrey_shapiro@dfci.harvard.edu

Assistant

Rachel Goldblatt
Dana-Farber Cancer Institute
Phone: 617-632-2096
rachel_goldblatt@dfci.harvard.edu

DF/HCC Program Affiliation

Translational Pharmacology and Early Therapeutic Trials
Lung Cancer

DF/HCC Associations

Member, Clinical Science Coordinating Committee

Research Abstract

I conduct both basic and translational research on cyclin-dependent kinase inhibitors. A major goal is to define the role of one of these inhibitors, p16ink4a in the cellular response to DNA damage. In addition, I am directing both preclinical and clinical studies of several potent pharmacologic cyclin-dependent kinase inhibitors. Several phase I trials are underway investigating these agents in patients with advanced solid tumors. The work involves the assessment of these drugs alone, as well as in combination with standard chemotherapy agents and signal transduction inhibitors.

Publications

View All Publications

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Geoffrey I. Shapiro, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School Associate Professor, Medical Oncology, Dana-Farber Cancer Institute Director, Early Drug Development Center, Dana-Farber Cancer Institute Contact Info Geoffrey Shapiro Dana-Farber Cancer Institute 450 Brookline Avenue Boston, MA, 02215 Mailstop: Mayer 446 Phone: 617-632-4942 Fax: 617-632-1977 geoffrey_shapiro@dfci.harvard.edu Assistant Rachel Goldblatt Dana-Farber Cancer Institute Phone: 617-632-2096 rachel_goldblatt@dfci.harvard.edu DF/HCC Program Affiliation Translational Pharmacology and Early Therapeutic Trials Lung Cancer DF/HCC Associations Member, Clinical Science Coordinating Committee Research Abstract I conduct both basic and translational research on cyclin-dependent kinase inhibitors. A major goal is to define the role of one of these inhibitors, p16ink4a in the cellular response to DNA damage. In addition, I am directing both preclinical and clinical studies of several potent pharmacologic cyclin-dependent kinase inhibitors. Several phase I trials are underway investigating these agents in patients with advanced solid tumors. The work involves the assessment of these drugs alone, as well as in combination with standard chemotherapy agents and signal transduction inhibitors. Publications View All Publications
Site Map Site Feedback Web Privacy Policy